The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma

被引:14
|
作者
Saito, Norihiko [1 ]
Hirai, Nozomi [1 ]
Aoki, Kazuya [1 ]
Suzuki, Ryo [1 ]
Fujita, Satoshi [1 ]
Nakayama, Haruo [1 ]
Hayashi, Morito [1 ]
Ito, Keisuke [1 ]
Sakurai, Takatoshi [1 ]
Iwabuchi, Satoshi [1 ]
机构
[1] Toho Univ, Ohashi Med Ctr, Dept Neurosurg, Tokyo 1538515, Japan
来源
CANCERS | 2019年 / 11卷 / 01期
关键词
NOTCH; glioma initiating cell; PTEN; PI3K pathway; glioblastoma; C-MYC; CELLS; PTEN; ACTIVATION; EXPRESSION; RESISTANCE; DIFFERENTIATION; GROWTH; GENES; ROLES;
D O I
10.3390/cancers11010121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The NOTCH pathway regulates neural stem cells and glioma initiating cells (GICs). However, blocking NOTCH activity with gamma-secretase inhibitors (GSIs) fails to alter the growth of GICs, as GSIs seem to be active in only a fraction of GICs lines with constitutive NOTCH activity. Here we report loss of PTEN function as a critical event leading to resistance to NOTCH inhibition, which causes the transfer of oncogene addiction from the NOTCH pathway to the PI3K pathway. Drug cytotoxicity testing of eight GICs showed a differential growth response to GSI, and the GICs were thus stratified into two groups: sensitive and resistant. In the sensitive group, GICs with loss of PTEN function appeared less sensitive to GSI treatment. Here we show that NOTCH regulates PTEN expression and the activity of the PI3K pathway in GICs, as treatment with GSI attenuated the NOTCH pathway and increased PTEN expression. NOTCH regulates PTEN expression via Hes-1, as knockdown of Notch or Hes1 increased expression of PTEN. This novel observation suggests that both pathways must be simultaneously inhibited in order to improve therapeutic efficacy in human glioblastomas (GBMs).
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Oncogene addiction switch from NOTCH to PI3K/AKT require simultaneous targeting of NOTCH and PI3K pathway inhibition in glioblastoma
    Saito, Norihiko
    Aoki, Kazuya
    Hirai, Nozomi
    Suzuki, Ryo
    Fujita, Satoshi
    Sato, Kenichiro
    Nakayama, Haruo
    Hayashi, Morito
    Sakurai, Takatoshi
    Iwabuchi, Satoshi
    BRAIN PATHOLOGY, 2019, 29 : 124 - 124
  • [2] ONCOGENE ADDICTION SWITCH FROM NOTCH TO PI3K REQUIRE SIMULTANEOUS TARGETING OF DUAL PATHWAY INHIBITION IN GLIOBLASTOMA
    Saito, Norihiko
    Aoki, Kazuya
    Hirai, Nozomi
    Suzuki, Ryo
    Fujita, Satoshi
    Nakayama, Haruo
    Hayashi, Morito
    Sakurai, Takatoshi
    Iwabuchi, Satoshi
    NEURO-ONCOLOGY, 2018, 20 : 52 - 52
  • [3] Notch and PI3K: how is the road traveled?
    Bailis, Will
    Pear, Warren S.
    BLOOD, 2012, 120 (07) : 1349 - 1350
  • [4] Targeting the PI3K pathway in cancer
    Workman, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S80 - S80
  • [5] Targeting the PI3K pathway in cancer
    Mills, GB
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S4 - S4
  • [6] Targeting PI3K
    Cantley, L.
    Lewis, C. Cantley
    CANCER RESEARCH, 2012, 72
  • [7] Targeting the PI3K pathway for cancer therapy
    Sadeghi, Navid
    Gerber, David E.
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (09) : 1153 - 1169
  • [8] Targeting the PI3K Pathway in Gynecologic Malignancies
    Monica Avila
    Michaela Onstad Grinsfelder
    Melissa Pham
    Shannon N. Westin
    Current Oncology Reports, 2022, 24 : 1669 - 1676
  • [9] Targeting the PI3K pathway in myeloproliferative neoplasms
    Gerds, Aaron T.
    Bartalucci, Niccolo
    Assad, Albert
    Yacoub, Abdulraheem
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 835 - 843
  • [10] Targeting the PI3K signaling pathway in cancer
    Wong, Kwok-Kin
    Engelman, Jeffrey A.
    Cantley, Lewis C.
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 2010, 20 (01) : 87 - 90